---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-060299"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-05-13T20:33:41+00:00"
generated_at: "2026-05-13T20:34:43.940729+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Armata posts Q1 net loss of $115.3M ($3.16/diluted share); secures $25M Innoviva loan

## Summary
- Net loss of $115.3M vs $6.5M in Q1 2025; loss includes non-cash items from warrant amendments.
- Revenue of $0.8M (grant) up from $0.5M; R&D spend $6.1M vs $5.4M; cash $4.8M down from $8.7M.
- Entered $25M secured term loan with Innoviva at 14% interest, maturing Jan 11, 2029.
- AP-SA02 Phase 3 superiority study in S. aureus bacteremia expected to start H2 2026; FDA granted QIDP and Fast Track.
- Appointed Daniel Gilmer to Board; ~36.7M shares outstanding as of May 8, 2026.

## SEC filing metadata
- accession: 0001104659-26-060299
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-05-13T20:33:41+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/0001104659-26-060299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/armp-20260512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-060299
- JSON: https://secwatch.observer/filing/0001104659-26-060299.json
- Plain text: https://secwatch.observer/filing/0001104659-26-060299.txt

## Key facts
- Debt Financings
  Armata Pharmaceuticals, Inc. incurred term loan of $25 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing January 11, 2029.
  - Instrument: term loan
  - Principal: $25 million
  - Counterparty: Innoviva Strategic Opportunities LLC
  - Rate: 14.0% per annum
  - Maturity: January 11, 2029
  - Event: incurrence
  source text: On May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 11, 2029.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/0001104659-26-060299-index.htm
- Earnings Releases
  Armata Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 13, 2026, the Company announced its financial results for the three months ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/0001104659-26-060299-index.htm
- Material Agreements
  Armata Pharmaceuticals, Inc. entered into May 2026 Credit Agreement with Innoviva Strategic Opportunities LLC (Innoviva) valued at $25 million (effective 2026-05-12).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Innoviva Strategic Opportunities LLC (Innoviva)
  - Value: $25 million
  - Effective: 2026-05-12
  source text: on May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/0001104659-26-060299-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.